Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~  * Progressive systemic (metastatic) disease despite castrate levels of testosterone secondary to orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist therapy~    * Castrate levels of testosterone must be maintained~   * LHRH analog therapy should be continued~ * Failed prior standard androgen-deprivation therapy~ * Serum testosterone no greater than 50 ng/mL for patients who have not had bilateral orchiectomy~* Evidence of metastatic disease on CT scan, MRI, or bone scan (no positron-emission tomography or prostascint)~* Evidence of progressive disease after most recent prior therapy (including hormonal therapy) as defined by 1 of the following:~  * Measurable disease progression~    * More than 20% increase in the sum of the longest diameters of target lesions from the time of maximal regression or the appearance of 1 or more new lesions~ * Bone scan progression~    * Appearance of 1 or more new lesions on bone scan attributable to prostate cancer AND~   * PSA at least 5 ng/mL~ * PSA progression~    * PSA at least 5 ng/mL which has increased serially from baseline on 2 occasions (at least 1 week apart) NOTE: If the confirmatory PSA is less than screening PSA, an additional test for rising PSA is required~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-2~Life expectancy~* Not specified~Hematopoietic~* Granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic~* AST and ALT no greater than 1.5 times upper limit of normal (ULN)~* Bilirubin no greater than ULN~Renal~* Creatinine no greater than 1.5 times ULN~Cardiovascular~* No myocardial infarction within the past year~* No significant change in anginal pattern within the past year~* No congestive heart failure~* No New York Heart Association class II-IV heart disease~* No deep vein thrombosis within the past year~Pulmonary~* No pulmonary embolus within the past year~Other~* No clinically significant peripheral neuropathy~* No known hypersensitivity to sulindac~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior cytotoxic chemotherapy (including estramustine or suramin)~* No other concurrent chemotherapy~Endocrine therapy~* See Disease Characteristics~* At least 4 weeks since prior flutamide and megestrol~* At least 6 weeks since prior bicalutamide and nilutamide~* At least 4 weeks since prior hormonal therapy known to decrease PSA levels (including ketoconazole, aminoglutethimide, finasteride, or any systemic corticosteroid)~* Concurrent primary testicular androgen suppression therapy (e.g., with a LHRH analog) allowed~* No other concurrent hormonal therapy except:~  * Steroids for adrenal insufficiency~ * Hormones for non-disease-related conditions (e.g., insulin for diabetes)~ * Intermittent dexamethasone as an antiemetic~Radiotherapy~* At least 4 weeks since prior radiotherapy and recovered~* At least 8 weeks since prior strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium~* No concurrent palliative radiotherapy~Surgery~* See Disease Characteristics~* At least 4 weeks since prior major surgery and recovered~Other~* At least 4 weeks since prior herbal product known to decrease PSA levels (including saw palmetto, PC-SPES)~* More than 1 week since prior sulindac~* No concurrent sulindac~* No concurrent chronic nonsteroidal anti-inflammatory drugs (including COX-2 inhibitors and salicylates such as aspirin, mesalamine, salsalate, and sulfasalazine)~  * Concurrent ibuprofen and naproxen allowed~ * Low-dose aspirin (e.g., 81 mg/day) for cardiovascular prevention allowed~* No concurrent full-dose oral or parenteral anticoagulation therapy~* Concurrent bisphosphonate therapy allowed provided therapy was initiated at least 4 weeks before study and disease has progressed despite therapy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combined chemotherapy (Type: EXPERIMENTAL): combination of 3 chemotherapy agents for hormone refractory prostate cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).